Du Changzheng

Associate Professor
School of Medicine


Du Changzheng, male, associate professor in South University of Science and Technology Medical School. He has been engaged in gastrointestinal oncology for more than ten years and is good at the multidisciplinary treatment and surgery of gastrointestinal tumor, especially the colorectal cancer. He has abundant clinical experience on the anal-sparing surgery for low rectal cancer, as well as the individual treatment after neoadjuvant chemoradiotherapy. He also has rich experience in basic research, including tumor molecular biology and epigenetics, with special interests on clinical translation of basic research. He has published more than 20 papers in first-class journals such as Cell Report and Cancer Letters. He owns an invention patent and a utility patent.


2006-2009    Peking University Cancer Hospital/Oncological School, Doctor Degree of Oncology

2001-2006    Peking University Health Science Center, Bachelor



2020.07-   Associate Professor, Southern University of Science and Technology Medicine School

2020.2-2020.5  Research Associate, Pathology Department, Duke University , USA

2017.5-2020.1  Postdoctoral Researcher, Pathology Department, Duke University , USA

2012.6  Short-term Visiting Scholar, Surgery Department, Yonsei University Hospital, Korea

2009.7-2020.3  Resident/Attending/Vice director doctor, Peking University Cancer Hospital



Peking University Innovation Award(2006)

Outstanding Graduate Award(2009)

The 7th National Symposium on Oncology for Young and Middle-aged Scholar, Outstanding Representation Award(2011)

Wuhan Anorectal Academic Summit Excellent Paper Award(2016)

Beijing Hospital Administration “Qingmiao” Funding(2017)

Possessing 1 patent for invention, 1 patent for utility



Prof. Du has been working as a first-line doctor in surgical treatment of digestive malignant tumor for more than 10 years, with abundant clinical experience. He delivered the first clinical trial of non-surgery treatment for rectal cancer in China, which was displayed at the 2018 ASCO meeting and included in Journal of Clinical Oncology. Prof. Du uses basic research to solve clinical problems, focusing on translating lab work into clinic use. The research fields including cancer molecular biology, signal pathway/ therapeutic targets, and epigenetics. Prof. Du has published more than 20 papers during the past decade in the first-class SCI journals, such as Cell Report, Cancer Letters and others.

Editorial member of the following journals:

International Journal of Disease Markers

SM Journal of Gastroenterology & Hepatology

International Journal of Disease Markers


Reviewers of the following journals:

British Journal of Cancer

Journal of Cancer

Plos One

Biomarkers & Applications

Journal of Wound Care

Cancer Medicine

Gastroenterology & Hepatology

International Journal of Disease Markers

Chinese Journal of Cancer Research

Experimental and Molecular Pathology

International Journal of Clinical Medicine

Journal of Gastric Cancer

Journal of Cellular and Molecular Medicine



Recent 5 years:

1.  Du, C.Z., et al., Value of intra-operative Doppler sonographic measurements in predicting post-operative anastomotic leakage in rectal cancer: a prospective pilot study. Chin Med J (Engl), 2019. 132(18): p. 2168-2176.

2.  Du, C., et al., A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis. Cell Rep, 2019. 28(12): p. 3199-3211 e5.

3.  Cao, L.L., et al., Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma. Int J Biol Markers, 2018: p. 1724600818764069.

4.  Tang, M., et al., Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer. Theranostics, 2017. 7(5): p. 1346-1359.

5.  Li, Z., et al., Characteristics and comparison of colorectal cancer incidence in Beijing with other regions in the world. Oncotarget, 2017. 8(15): p. 24593-24603.

6.  Huang, D., et al., Overexpression of LAMC2 predicts poor prognosis in colorectal cancer patients and promotes cancer cell proliferation, migration, and invasion. Tumour Biol, 2017. 39(6): p. 1010428317705849.

7.  Du, C., et al., Use of a combination of CEA and tumor budding to identify high-risk patients with stage II colon cancer. Int J Biol Markers, 2017. 32(3): p. e267-e273.

8.  Du, C., et al., 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. Cancer Lett, 2017. 400: p. 183-193.

9.  Pan, H.D., et al., Subcutaneous vacuum drains reduce surgical site infection after primary closure of defunctioning ileostomy. Int J Colorectal Dis, 2015. 30(7): p. 977-82.